← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
zolbetuximab
L01FX31
Forms & Strengths
- intravenous solution 10 mg/mL
- single-dose vial 100 mg/10 mL
- single-dose vial 500 mg/50 mL
Adult Dosing
- initial dose 10 mg/kg on day 1
- subsequent doses 10 mg/kg every 2 weeks
- administer as an intravenous infusion over 60 minutes
Pediatric Dosing
- safety and efficacy not established in pediatric patients
- use in pediatric patients is not recommended
Indications
- gastric/gastroesophageal junction adenocarcinoma
- squamous cell carcinoma of the esophagus
- first-line treatment in combination with chemotherapy
Mechanism of Action
- monoclonal antibody targeting claudin 18.2
- inhibits tumor cell growth and induces cell death
- enhances antitumor activity of chemotherapy
Contraindications
- hypersensitivity to zolbetuximab or any component
- pregnancy and lactation
Adverse Reactions
- infusion-related reactions
- fatigue
- decreased appetite
- nausea
- vomiting
- diarrhea
- abdominal pain
Drug Interactions
- no significant interactions with CYP450 enzymes
- potential increased risk of adverse reactions with other monoclonal antibodies
Curated Content: Needs Vetting Before Put to Clinical Use